Cabaletta Bio (CABA) Operating Income (2018 - 2026)
Cabaletta Bio (CABA) posted quarterly Operating Income of -$42.6 million for Q4 2025, down 26.12% year-over-year from -$57.7 million in Q4 2024, and up 8.54% quarter-over-quarter from -$46.6 million in Q3 2025.
Cabaletta Bio (CABA) Operating Income (2018 - 2026) Analysis & Trends
Cabaletta Bio's Operating Income history runs 8 years deep, the most recent figure standing at -$42.6 million for Q4 2025.
- In Q4 2025, Operating Income fell 26.12% year-over-year to -$42.6 million; the TTM figure through Dec 2025 stood at -$172.2 million (down 37.64% YoY), while the FY2025 annual figure was -$172.2 million, down 37.64% from the prior year.
- Operating Income for Q4 2025 stood at -$42.6 million, up from -$46.6 million in the prior quarter.
- The five-year high for Operating Income was -$9.7 million in Q1 2021, with the low at -$46.6 million in Q3 2025.
- The 5-year median for Operating Income is -$17.8 million (2023), against an average of -$23.6 million.
- The sharpest annual moves came in 2022 and 2024: Operating Income fell 1.86% in 2022, then tumbled 90.55% in 2024.
- Cabaletta Bio's Operating Income stood at -$13.9 million in 2021, then declined by 17.34% to -$16.3 million in 2022, then sank by 41.98% to -$23.1 million in 2023, then tumbled by 45.96% to -$33.8 million in 2024, then dropped by 26.12% to -$42.6 million in 2025.
- Business Quant data shows CABA's Operating Income at -$42.6 million in Q4 2025, -$46.6 million in Q3 2025, and -$45.9 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 493.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 325.05 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,158.03 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 133.12 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 231.44 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.55 Mn |
| 10 | Cabaletta Bio | 466.25 Mn | 466.25 Mn | - | -52.02 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -52.02 Mn |
| Dec 31, 2025 | -42.61 Mn |
| Sep 30, 2025 | -46.59 Mn |
| Jun 30, 2025 | -45.91 Mn |
| Mar 31, 2025 | -37.14 Mn |
| Dec 31, 2024 | -33.79 Mn |
| Sep 30, 2024 | -33.05 Mn |
| Jun 30, 2024 | -30.28 Mn |
| Mar 31, 2024 | -28.03 Mn |
| Dec 31, 2023 | -23.15 Mn |
| Sep 30, 2023 | -18.67 Mn |
| Jun 30, 2023 | -15.89 Mn |
| Mar 31, 2023 | -16.96 Mn |
| Dec 31, 2022 | -16.30 Mn |
| Sep 30, 2022 | -11.78 Mn |
| Jun 30, 2022 | -13.06 Mn |
| Mar 31, 2022 | -13.00 Mn |
| Dec 31, 2021 | -13.89 Mn |
| Sep 30, 2021 | -11.56 Mn |
| Jun 30, 2021 | -11.15 Mn |